Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8200916 | 0.78 | EGFR (0.57) | CSF1RKDM1ATSHRMAOA | |
| SCHEMBL23147570 | 0.76 | MEN1 (0.51) | MEN1APAF1KMT2AKDM1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL4731344 | 0.76 | EGFR (0.56) | CSF1RKDM1ATSHR | |
| SCHEMBL3483183 | 0.73 | EGFR (0.41) | ALDH1A1CYP3A4TSHRTDP1MAP4K4 | |
| SCHEMBL8515345 | 0.71 | MEN1 (0.58) | MEN1APAF1KMT2AKDM1AALDH1A1 | |
| SCHEMBL13282750 | 0.70 | MEN1 (0.56) | MEN1APAF1KMT2AKDM1AALDH1A1 | |
| SCHEMBL21808761 | 0.70 | RAB9A (0.49) | MEN1KMT2AALDH1A1TSHRMAP4K4 | |
| SCHEMBL580112 | 0.70 | MEN1 (0.56) | MEN1APAF1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL13282548 | 0.70 | MEN1 (0.56) | MEN1APAF1KMT2AKDM1AALDH1A1 | |
| SCHEMBL2460533 | 0.70 | KMT2A (0.56) | MEN1APAF1KMT2AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4294804-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | MEN1 3040/4885APAF1 2286/4885KMT2A 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.